Enliven Therapeutics, Inc.
Support and Resistance Levels
Past performance
News About ELVN
All events for ELVN
All deals for ELVN
Financial Ratios
Financial Statements
ELVN vs Sector & Peers
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado. Website enliventherapeutics.com
Headquarters Boulder, CO, US